Current updates on the epidemiology, pathogenesis and development of small molecule therapeutics for the treatment of Ebola virus infections

Abstract

Ebola virus disease (EVD) is a rare, highly contagious and a deadly disease with a variable fatality rate ranging from 30% to 90%. Over the past two decades, Ebola pandemic has severely affected the sub-Sahara region including Democratic Republic of the Congo (DRC), and Uganda. The causative agents of the most EVD cases are three distinct species out of six Ebolaviruses namely Zaire Ebolavirus (ZEBOV), Sudan Ebolavirus (SUDV) and Bundibugyo Ebolavirus (BDBV). In recent years, significant strides have been made in therapeutic interventions. Notably, the US Food and Drug Administration has approved two monoclonal antibodies: Inmazeb^TM (REGN-EB3) and Ansuvimab or Ebanga™. Additionally, many small molecules are currently in the developmental stage, promising further progress in medical treatment. Addressing the critical need for preventive measures, this review provides an in-depth analysis of the licensed Ebola vaccines-Ervebo and the combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) as well as the vaccines which are currently being tested for their efficacy and safety in clinical studies. These vaccines might play an important role in curbing the spread and mitigating the impact of this lethal disease. The current treatment landscape for EVD encompasses both nutritional (supportive) and drug therapies. The review comprehensively details the origin, pathogenesis, and epidemiology of EVD, shedding light on the ongoing efforts to combat this devastating disease. It explores small molecules in various stages of the development, discusses patents filed or granted, and delves into the clinical and supportive therapies that form the cornerstone of EVD management. This review aims to provide the recent developments made in the design and synthesis of small molecules for scientific community to facilitate a deeper understanding of the disease and fostering the development of effective strategies for prevention, treatment, and control of EVD.

Keywords

Ebola / Epidemic / Vaccine / Ebola virus disease

References

[1] Burk R, Bollinger L, Johnson JC, Wada J, Radoshitzky SR, Palacios G, et al. Neglected filoviruses. FEMS Microbiol Rev 2016; 40(4): 494-519.

[2] Mashkoor Y, Rafique F, Zubair A. Recurrent Marburg virus disease outbreaks from 1967 to 2022: A perspective on challenges imposed and future implications. Asian Pac J Trop Med 2022; 15(9): 385-386.

[3] Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, Vega M-AdL, et al. Ebola virus disease. Nat Rev Dis Primers 2020; 6(1): 13. doi: 10.1038/s41572-020-0147-3.

[4] Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438(7068): 575-576.

[5] WHO . Ebola virus disease. [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease. [Accessed on 8 December 2023].

[6] Prevention CFDCa. History of Ebola disease outbreaks 2023. [Online]. Available from: https://www.cdc.gov/vhf/ebola/history/chronology.html. [Accessed on 8 December 2023].

[7] Kennedy SB, Nisbett RA. The Ebola epidemic: A transformative moment for global health. Bull World Health Organ 2015; 93(1): 2.

[8] Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377(9768): 849-862.

[9] Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med 2010; 30(1): 161-177.

[10] Nicastri E, Kobinger G, Vairo F, Montaldo C, Mboera LEG, Ansunama R, et al. Ebola virus disease: Epidemiology, clinical features, management, and prevention. Infect Dis Clin North Am 2019; 33(4): 953-976.

[11] Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988; 297(6648): 584-587.

[12] Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56(2): 271-293.

[13] Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis 1999; 179(Suppl 1): S1-S7.

[14] Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC. Ebola virus disease: A review on epidemiology, symptoms, treatment and pathogenesis. Neth J Med 2014; 72(9): 442-448.

[15] Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The pathogenesis of Ebola virus disease. Annu Rev Pathol 2017; 12: 387-418.

[16] Volchkov VE, Volchkova VA, Chepurnov AA, Blinov VM, Dolnik O, Netesov SV, et al. Characterization of the L gene and 5' trailer region of Ebola virus. J Gen Virol 1999; 80(Pt 2): 355-362.

[17] Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76(10): 4855-4865.

[18] Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 1998; 95(10): 5762-5767.

[19] Rivera A, Messaoudi I. Molecular mechanisms of Ebola pathogenesis. J Leukoc Biol 2016; 100(5): 889-904.

[20] Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017; 389(10068): 505-518.

[21] Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 2017; 377(15): 1438-1447.

[22] WHO . Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: An example of integration of research into epidemic response. [Online]. Available from: https://terrance.who.int/mediacentre/data/sage/SAGE_Docs_Ppt_Oct2019/7_session_ebola/Oct2019_Session7_preliminary_efficacy_results_Ebola_vaccine.pdf. [Accessed on 8 December 2023].

[23] Alirol E, Kuesel AC, Guraiib MM, de la Fuente-Núñez V, Saxena A, Gomes MF. Ethics review of studies during public health emergencies-the experience of the WHO ethics review committee during the Ebola virus disease epidemic. BMC Med Ethics 2017; 18(1): 43.

[24] Tomori O, Kolawole MO. Ebola virus disease: Current vaccine solutions. Curr Opin Immunol 2021; 71: 27-33.

[25] Lee JS, Adhikari NKJ, Kwon HY, Teo K, Siemieniuk R, Lamontagne F, et al. Anti-Ebola therapy for patients with Ebola virus disease: A systematic review. BMC Infect Dis 2019; 19(1): 376.

[26] Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, et al. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine 2017; 35(35 Pt A): 4465-4469.

[27] Capelle MAH, Babich L, van Deventer-Troost JPE, Salerno D, Krijgsman K, Dirmeier U, et al. Stability and suitability for storage and distribution of Ad26. ZEBOV/MVA-BN^®-Filo heterologous prime-boost Ebola vaccine. Eur J Pharm Biopharm 2018; 129: 215-221.

[28] Wu F, Zhang S, Zhang Y, Mo R, Yan F, Wang H, et al. A chimeric Sudan virus-like particle vaccine candidate produced by a recombinant Baculovirus system induces specific immune responses in mice and horses. Viruses 2020; 12(1): 64.

[29] Lehrer AT, Wong TS, Lieberman MM, Johns L, Medina L, Feldmann F, et al. Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. Vaccine 2019; 37(47): 6942-6950.

[30] Boum Y, Juan-Giner A, Hitchings M, Soumah A, Strecker T, Sadjo M, et al. Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea. Vaccine 2020; 38(31): 4877-4884.

[31] Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, Ndour CT, et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: A randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2020; 20(6): 707-718.

[32] Pavot V. Ebola virus vaccines: Where do we stand? Clin Immunol 2016; 173: 44-49.

[33] Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385(9984): 2272-2279.

[34] Wikipedia . Ebola vaccine. [Online]. Available from: https://en.wikipedia.org/wiki/Ebola_vaccine. [Accessed on 9 December 2023].

[35] Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013; 9(5): e1003389.

[36] Sivanandy P, Jun PH, Man LW, Wei NS, Mun NFK, Yii CAJ, et al. A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. J Infect Public Health 2022; 15(3): 285-292.

[37] Mulangu S, Dodd LE, Davey RT Jr. , Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381(24): 2293-2303.

[38] Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514(7520): 47-53.

[39] Uyeki TM, Mehta AK, Davey RT Jr. , Liddell AM, Wolf T, Vetter P, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 2016; 374(7): 636-646.

[40] Sivapalasingam S, Kamal M, Slim R, Hosain R, Shao W, Stoltz R, et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: A randomised, first-in-human phase 1 study. Lancet Infect Dis 2018; 18(8): 884-893.

[41] Lucey DR. New treatments for Ebola virus disease. BMJ 2019; 366: l5371.

[42] Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J Infect Dis 2018; 218(suppl_5): S612-S626.

[43] Tshiani Mbaya O, Mukumbayi P, Mulangu S. Review: Insights on current FDA-approved monoclonal antibodies against Ebola virus infection. Front Immunol 2021; 12: 721328.

[44] Lee A. Ansuvimab: First approval. Drugs 2021; 81(5): 595-598.

[45] Markham A. REGN-EB3: First approval. Drugs 2021; 81(1): 175-178.

[46] Fanunza E, Frau A, Corona A, Tramontano E. Antiviral agents against Ebola virus infection: Repositioning old drugs and finding novel small molecules. Annu Rep Med Chem 2018; 51: 135-173.

[47] Dixit D, Masumbuko Claude K, Kjaldgaard L, Hawkes MT. Review of Ebola virus disease in children-how far have we come? Paediatr Int Child Health 2021; 41(1): 12-27.

[48] Hasan S, Ahmad SA, Masood R, Saeed S. Ebola virus: A global public health menace: A narrative review. J Family Med Prim Care 2019; 8(7): 2189-2201.

[49] Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, et al. BCX4430-A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 2016; 9(3): 220-226.

[50] Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, et al. The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus. iScience 2019; 19: 1279-1290.

[51] DeWald LE, Johnson JC, Gerhardt DM, Torzewski LM, Postnikova E, Honko AN, et al. In vivo activity of amodiaquine against Ebola virus infection. Sci Rep 2019; 9(1): 20199.

[52] Madelain V, Duthey A, Mentré F, Jacquot F, Solas C, Lacarelle B, et al. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates. Antiviral Res 2020; 177: 104758.

[53] Lane TR, Massey C, Comer JE, Freiberg AN, Zhou H, Dyall J, et al. Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. Antiviral Res 2020; 181: 104863.

[54] Lane TR, Dyall J, Mercer L, Goodin C, Foil DH, Zhou H, et al. Repurposing Pyramax^®, quinacrine and tilorone as treatments for Ebola virus disease. Antiviral Res 2020; 182: 104908.

[55] Ekins S, Lane TR, Madrid PB. Tilorone: A broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond. Pharm Res 2020; 37(4): 71.

[56] Yoon YS, Jang Y, Hoenen T, Shin H, Lee Y, Kim M. Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. BMB Rep 2020; 53(3): 166-171.

[57] Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: From Ebola to COVID-19. Drugs Context 2020; 9: 2020-4-14. doi: 10.7573/dic.2020-4-14.

[58] Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009; 83(3): 245-251.

[59] Hodge T, Draper K, Brasel T, Freiberg A, Squiquera L, Sidransky D, et al. Antiviral effect of ranpirnase against Ebola virus. Antiviral Res 2016; 132: 210-218.

[60] Dowall SD, Bewley K, Watson RJ, Vasan SS, Ghosh C, Konai MM, et al. Antiviral screening of multiple compounds against Ebola virus. Viruses 2016; 8(11): 277.

[61] Luthra P, Liang J, Pietzsch CA, Khadka S, Edwards MR, Wei S, et al. A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication. Antiviral Res 2018; 150: 193-201.

[62] Luthra P, Naidoo J, Pietzsch CA, De S, Khadka S, Anantpadma M, et al. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Res 2018; 158: 288-302.

[63] Sun W, He S, Martínez-Romero C, Kouznetsova J, Tawa G, Xu M, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res 2017; 137: 165-172.

[64] Cheng H, Schafer A, Soloveva V, Gharaibeh D, Kenny T, Retterer C, et al. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. Antiviral Res 2017; 145: 24-32.

[65] Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, et al. Identification of diaryl-quinoline compounds as entry inhibitors of Ebola virus. Viruses 2018; 10(12): 678.

[66] Sakurai Y, Sakakibara N, Toyama M, Baba M, Davey RA. Novel amodiaquine derivatives potently inhibit Ebola virus infection. Antiviral Res 2018; 160: 175-182.

[67] Pessi A, Bixler SL, Soloveva V, Radoshitzky S, Retterer C, Kenny T, et al. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. Antiviral Res 2019; 171: 104592.

[68] Penny CJ, Vassileva K, Jha A, Yuan Y, Chee X, Yates E, et al. Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochim Biophys Acta Mol Cell Res 2019; 1866(7): 1151-1161.

[69] Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, et al. Discovery and structural optimization of 4-(Aminomethyl) benzamides as potent entry inhibitors of Ebola and Marburg virus infections. J Med Chem 2020; 63(13): 7211-7225.

[70] Goyal S, Binnington B, McCarthy SDS, Desmaële D, Férrié L, Figadère B, et al. Inhibition of in vitro Ebola infection by anti-parasitic quinoline derivatives. F1000Res 2020; 9: 268.

[71] Bessières M, Plebanek E, Chatterjee P, Shrivastava-Ranjan P, Flint M, Spiropoulou CF, et al. Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of Ebola virus infection. Eur J Med Chem 2021; 214: 113211.

[72] Lasala F, García-Rubia A, Requena C, Galindo I, Cuesta-Geijo MA, García-Dorival I, et al. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses. Antiviral Res 2021; 186: 105011.

[73] Han S, Li H, Chen W, Yang L, Tong X, Zuo J, et al. Discovery of potent Ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold. Eur J Med Chem 2022; 240: 114608.

[74] Plescia CB, Lindstrom AR, Quintero MV, Keiser P, Anantpadma M, Davey R, et al. Evaluation of phenol-substituted diphyllin derivatives as selective antagonists for Ebola virus entry. ACS Infect Dis 2022; 8(5): 942-957.

[75] Garcia-Rubia A, Lasala F, Ginex T, Morales-Tenorio M, Olal C, Heung M, et al. N'-Phenylacetohydrazide derivatives as potent Ebola virus entry inhibitors with an improved pharmacokinetic profile. J Med Chem 2023; 66(8): 5465-5483.

[76] Haikal MC, Nasution MAF, Saputro L, Tambunan USF, editors . In silico identification of potent inhibitors of heat shock protein 90 (Hsp90) from Indonesian natural product compounds as a novel approach to treat ebola virus disease. 2019 IOP Conf Ser: Mater Sci Eng 2019; 509: 012082. doi: 10.1088/1757-899X/509/1/012082.

[77] Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, et al. Engineered human cathelicidin antimicrobial peptides inhibit Ebola virus infection. iScience 2020; 23(4): 100999.

[78] Biedenkopf N, Lange-Grünweller K, Schulte FW, Weiβer A, Müller C, Becker D, et al. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antiviral Res 2017; 137: 76-81.

[79] Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The natural product eugenol is an inhibitor of the Ebola virus in vitro. Pharm Res 2019; 36(7): 104.

[80] Kwofie SK, Broni E, Teye J, Quansah E, Issah I, Wilson MD, et al. Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. Comput Biol Med 2019; 113: 103414.

[81] Tsang NY, Li WF, Varhegyi E, Rong L, Zhang HJ. Ebola entry inhibitors discovered from Maesa perlarius. Int J Mol Sci 2022; 23(5): 2620. doi: 10.3390/ijms23052620.

[82] Ververs M, Arya A. Ebola virus disease and breastfeeding: Time for attention. Lancet 2019; 394(10201): 825.

[83] Lamontagne F, Fowler RA, Adhikari NK, Murthy S, Brett-Major DM, Jacobs M, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet 2018; 391(10121): 700-708.

[84] Aluisio AR, Perera SM, Yam D, Garbern S, Peters JL, Abel L, et al. Vitamin A supplementation was associated with reduced mortality in patients with Ebola virus disease during the West African outbreak. J Nutr 2019; 149(10): 1757-1765.

[85] Chaiyasit K, Wiwanitkit V. Nutritional management in Ebola haemorrhagic fever. Asian Pac J Trop Dis 2015; 5(Suppl. 1): S11-S12. doi: 10.1016/S2222-1808(15)60846-5.

[86] Henwood PC, Bebell LM, Roshania R, Wolfman V, Mallow M, Kalyanpur A, et al. Ebola virus disease and pregnancy: A retrospective cohort study of patients managed at 5 Ebola treatment units in West Africa. Clin Infect Dis 2017; 65(2): 292-299.

[87] Black BO, Caluwaerts S, Achar J. Ebola viral disease and pregnancy. Obstet Med 2015; 8(3): 108-113.

[88] Tumwine JK. Ebola and other issues in the health sector in Africa. Afr Health Sci 2014; 14(3): i-iii.

[89] Geraldo JM, Alfenas RdC. Role of diet on chronic inflammation prevention and control: Current evidences. Arquivos Brasileiros de Endocrinologia & Metabologia 2008; 52: 951-967.

[90] Cerón Rodríguez JM, Puertollano Vacas M, Puertollano Vacas ME, Alvarez de Cienfuegos López G. [Immunomodulatory role of dietary lipids in an immunosuppressed mouse model and infected with listeria monocytogenes]. Nutr Hosp 2014; 30(4): 837-844.

[91] Chambial S, Dwivedi S, Shukla KK, John PJ, Sharma P. Vitamin C in disease prevention and cure: An overview. Indian J Clin Biochem 2013; 28(4): 314-328.

[92] Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(Suppl 1): S18-S23.

[93] Keshtkar-Jahromi M, Martins KAO, Cardile AP, Reisler RB, Christopher GW, Bavari S. Treatment-focused Ebola trials, supportive care and future of filovirus care. Expert Rev Anti Infect Ther 2018; 16(1): 67-76.